| Survival: | 8.5 months |
| Toxicity Grade: | 4 |
| Treatments: | Chemotherapy |
| Drugs: | Doxil |
| Country: | United States |
| City/State/Province: | Houston, Texas |
| Hospital: | The University of Texas M.D. Anderson Cancer Center |
| Journal: | Link |
| Date: | 8/2000 |
| Description: |
| Patients: This Phase II study involved 24 patients with malignant pleural mesothelioma Treatment: The treatment consisted of the administration of the drug Doxil. Toxicity: Toxicities included cardiac, mild elevations of alkaline phosphatase, nausea, and hematological. One patient had a grade 4 neutropenia. Results: No objective responses were observed and the overall median survival was 37 weeks (8.5 months). Support: The study was supported in part by Sequus Pharmaceuticals, Inc. Sequus manufactures Doxil. Correspondence: Dong M. Shin, MD |